The MPA Pharma ransomware claim appeared on Rhysida’s leak site on 18 September 2026. Although the group alleges a major data theft, the available listing provides no files, screenshots or other evidence that independently confirms a breach.
The report should therefore be treated as an unverified allegation, not confirmation that MPA Pharma’s systems were compromised. This distinction is particularly important because previous listings attributed to Rhysida have reportedly included fabricated or otherwise unverified victim claims.
What the MPA Pharma ransomware listing claims
Rhysida named MPA Pharma, described in the listing as an internationally active pharmaceutical import and trading company, on its dark web leak site. The post alleges that the group obtained approximately 2,899,290 files with a combined volume of about 5.8 TB.
The listing date is 18 September 2026. No separate intrusion, discovery or compromise date was supplied, meaning there is no verified timeline showing when attackers may have entered the organisation, how long any access lasted or when the alleged information was extracted.
The MPA Pharma ransomware post does not say whether systems were encrypted or business operations were disrupted. It also provides no ransom demand, payment deadline, auction details or requested cryptocurrency amount. Based on the available information, the post is framed primarily as a data leak claim rather than a documented encryption incident.
Business, financial and regulatory records
Rhysida claims that the allegedly stolen material includes accounting records, database backups and SQL backups. It also refers to commercial registration documents, organisational information, credentials and internal IT artefacts.
The group further alleges that it obtained government audit records connected with customs, corporate taxation, social security and wage taxation. According to the leak page description, some of these records concern disputed or outstanding amounts. No underlying documents have been published in the material available through the report, so their authenticity and context cannot be assessed.
Another part of the MPA Pharma ransomware allegation concerns controlled substances. The listing refers to permits, reconciliations and records relating to opioids, cannabis and chemical precursors. It also claims that the material discusses documentation gaps, but there is no supporting evidence showing whether those records exist, are current or relate to MPA Pharma.
Litigation and arbitration files are also included in Rhysida’s description. If genuine, such documents could contain commercially sensitive or legally privileged information. However, the leak page summary does not identify individual cases or provide samples that would allow independent verification.
Personal, medical and commercial information
The listing alleges exposure of executive and employee personal information, leadership contact details, identity documents and passports. Payment card information is also mentioned, although the available description does not establish the type, quantity or validity of any card data.
Rhysida additionally claims to hold medical documentation and pharmacovigilance correspondence. Pharmacovigilance records can relate to the monitoring and reporting of medicine safety issues, but the post does not identify affected products, patients, healthcare professionals or reporting periods.
Commercially sensitive information is another part of the claim. The group refers to rebate agreements, other commercial agreements, ownership records and beneficial ownership materials. As with the other categories, no public sample is presented to demonstrate that the information came from MPA Pharma.
The leak description mentions a report containing password file information. It does not reproduce credential values or explain whether any alleged passwords are readable, hashed, current or associated with active accounts. The presence and usability of credentials therefore remain unknown.
Why the Rhysida claim remains unconfirmed
The strongest limitation of the MPA Pharma ransomware report is the absence of corroborating evidence. The leak page reportedly contains no screenshots or other images, and no downloadable files are identified. There is also no cited statement from MPA Pharma or an independent incident responder confirming an intrusion.
RedPacket Security, which recorded the listing, included a specific verification alert. It warned that listings attributed to Rhysida have reportedly included unverified or fabricated victim claims and advised readers to treat this post as unconfirmed until independent evidence emerges.
The reporting site also states that it did not download, view, host, republish or disclose any allegedly stolen information. Its page was generated from a redacted and automated collection of information displayed on Rhysida’s Tor-based leak site. Consequently, the report records what the ransomware group asserted, rather than validating the substance of that assertion.
No attack vector, malware sample, forensic indicator or exploited vulnerability is disclosed. The post does not identify any affected software product, operating system, appliance or version. There is therefore no basis for connecting the claim to a particular security flaw or advising organisations to patch a product specifically because of this listing.
Current exploitation and disclosure status
As of the 18 September 2026 report, the only established event is the appearance of MPA Pharma’s name and the associated claims on Rhysida’s leak site. The available material does not confirm encryption, continuing network access, publication of stolen files or active exploitation of a named vulnerability.
It is also unclear whether Rhysida contacted MPA Pharma before publishing the listing. There is no confirmed negotiation timeline, extortion deadline or evidence of a completed data sale or release. The claimed 5.8 TB volume should not be treated as verified merely because it is stated with apparent precision.
Why the MPA Pharma ransomware claim matters
The allegations cover a broad mixture of financial, regulatory, medical, identity and commercial information. If later substantiated, the scope could require careful assessment of affected individuals, contractual obligations and applicable reporting requirements.
For now, presenting the claim as a confirmed breach could amplify an unsupported criminal allegation. Organisations monitoring ransomware activity should clearly separate threat actor statements from independently verified incident facts, especially when a group’s previous claims have been questioned.
What organisations should do next
There is no event-specific patch or technical indicator in the MPA Pharma ransomware listing. Organisations should not make product changes based solely on this post, but security teams can use the allegation as a prompt to confirm that existing ransomware controls are operating as intended.
- Monitor for verified statements from MPA Pharma, regulators or incident response organisations.
- Treat any data samples that later appear as potentially sensitive and do not download them merely to investigate the claim.
- Review alerts for unusual access to backup stores, databases, identity repositories and large outbound transfers.
- Check that privileged and remote access accounts use strong authentication and that exposed credentials can be revoked quickly.
- Keep internal reporting factual by labelling Rhysida’s assertions as unconfirmed unless independent evidence becomes available.
The status of this event could change if MPA Pharma issues a statement, investigators publish findings or Rhysida releases verifiable material. Until then, the evidence supports describing it only as an uncorroborated leak-site listing.
Originally reported by redpacketsecurity.com.
